Relay Therapeutics, Inc. financials

RLAY CIK 0001812364

Source: EDGAR filings · Built 2026-06-04T02:29:28Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -235.87M -251.13M -304.44M -238.55M -77.88M -104.42M
EBITDA -299.18M -367.00M -367.73M -295.14M -360.77M -52.25M
Working Capital 552.70M 758.48M 739.83M 955.80M 951.92M 756.47M
Net Debt -51.56M -75.78M -90.27M -94.05M -257.22M -423.22M
Operating Margin -1971.59% -3722.07% -1460.11% -21670.89% -12040.21% -67.51%
Net Margin -1800.58% -3374.72% -1338.66% -21036.13% -12012.94% -63.41%
Return on Equity (ROE) -48.76% -43.42% -45.48% -30.57% -40.53% -6.87%
Return on Assets (ROA) -44.50% -38.76% -40.52% -26.42% -36.08% -6.55%
Current Ratio 22.61× 15.95× 25.44× 16.00× 40.14× 56.49×
Debt-to-Equity 0.06× 0.06× 0.07× 0.06× 0.03× 0.03×
Cash Conversion Ratio 0.85× 0.74× 0.88× 0.79× 0.20× 1.96×
Accruals Ratio -0.07× -0.10× -0.05× -0.06× -0.29× 0.06×
SBC % of Revenue 406.51% 940.73% 336.77% 4065.03% 1599.67% 38.67%
CapEx Coverage -574.28× -123.44× -72.79× -25.32× -21.44× -53.08×
Free Cash Flow Per Share $-1.37 $-1.75 $-2.48 $-2.13 $-0.82 $-2.45

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 95.79× 69.07× 54.93× 1310.22× 1097.11× 45.21×
P/B 2.59× 0.89× 1.87× 1.90× 3.70× 4.90×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 15.36M 10.01M 25.55M 1.38M 3.03M 82.65M
Revenues 15.36M 10.01M 25.55M 1.38M 3.03M 82.65M
Research and Development Expense 99.86M
Operating Expenses 318.09M 382.48M 398.55M 300.66M 367.73M 138.45M
Operating Income (Loss) -302.74M -372.47M -373.00M -299.27M -364.70M -55.80M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -276.48M -337.71M -341.97M -290.51M -363.87M -52.41M
Earnings Per Share, Basic $-1.61 $-2.36 $-2.79 $-2.59 $-3.82 $-5.40
Weighted Average Number of Shares Outstanding, Basic 171.59M 142.87M 122.58M 112.23M 95.14M 42.62M
Earnings Per Share, Diluted $-1.61 $-2.36 $-2.79 $-2.59 $-3.82 $-5.40
Weighted Average Number of Shares Outstanding, Diluted 112.23M 95.14M 42.62M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 84.02M 124.29M 143.74M 151.79M 280.12M 447.65M
Assets, Current 578.28M 809.20M 770.10M 1.02B 976.24M 770.10M
Assets 621.33M 871.30M 843.98M 1.10B 1.01B 799.83M
Liabilities, Current 25.58M 50.73M 30.27M 63.71M 24.32M 13.63M
Liabilities 54.27M 93.50M 91.98M 149.55M 110.64M 36.54M
Stockholders' Equity Attributable to Parent 567.06M 777.79M 752.00M 950.22M 897.81M 763.29M
Common Stock, Shares, Outstanding 173.87M 167.76M 127.46M 121.11M 108.21M 89.91M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -235.46M -249.11M -300.32M -229.49M -74.41M -102.49M
Payments to Acquire Property, Plant, and Equipment 410.00K 2.02M 4.13M 9.06M 3.47M 1.93M
Net Cash Provided by (Used in) Investing Activities 192.80M -41.08M 257.63M -188.75M -479.51M 81.67M
Net Cash Provided by (Used in) Financing Activities 1.60M 270.15M 34.75M 289.91M 388.09M 426.51M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (RLAY CIK 0001812364), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

KIM

KIMCO REALTY CORPORATION

SMPL

The Simply Good Foods Company

CADL

CANDEL THERAPEUTICS, INC.